RemovedRisk Factors
In addition, as federal, state and local governments consider adopting new privacy and security legislation, our operations may be subject to different standards in different geographical regions. This may require significantly more resources for compliance and increase the risk of regulatory enforcement and private litigation with respect to our privacy and security practices.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are also subject to the General Data Protection Regulation (“GDPR”), the primary data protection law in the European Economic Area, including the European Union (collectively, the “EU”), as well as associated EU member state data protection laws and the UK GDPR in the United Kingdom. These laws impose significant requirements for covered businesses (controllers and processors) of personal data, including, for example, standards for obtaining consent from individuals to process their personal data, disclosures to individuals, an individual data rights regime, specified timelines for data breach notifications, limitations on retention and secondary uses of information, requirements pertaining to health data and pseudonymised (i.e., deidentified) data, restrictions on data transfers outside of the EU, and obligations when we contract third-party processors in connection with the processing of personal data. The GDPR allows EU member states certain flexibility to make additional laws and regulations concerning the same issues, including, for example, further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of the GDPR may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. Other administrative penalties may be imposed under the applicable national data protection laws of the EU member states.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
We also have to comply with a number of data privacy laws that apply to cross border data transfers including those in the EU, Switzerland, UK, Brazil and China. These may result in increased compliance costs and complexity when transferring data internationally.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
Data residency and localization laws have also been passed or are under consideration in several countries (such as China and Russia), which require personal information relating to their citizens to be maintained on local servers and impose additional data transfer restrictions.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
Finally, the last few years have seen a number of U.S. federal and state regulatory efforts around the use of artificial intelligence. Like privacy and security, this is a quickly evolving patchwork of guidance, rules, and regulation from a number of legislative bodies, agencies, and other authorities. In the European Union, even more comprehensive and prescriptive requirements over artificial intelligence have been enacted in the form of the EU AI Act, which went into effect on August 1, 2024 with varying implementation deadlines. To the extent our efforts in research and innovation entail or embed the use of artificial intelligence into our products and services, or to the extent we leverage artificial intelligence in our internal operations (either directly or through third-party vendors), such legal and regulatory changes could ultimately apply to and thus impact our company’s practices.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RewordedRisk Factors
This indebtedness could adversely affect our businesses and our ability to meet our obligations.As of February 7, 2025, 6, 2026, we had outstanding indebtedness of approximately $1.4 $1.5 billion, including approximately $793.6 $960.6 million under our Second second amended credit agreement (the “Second Amended Credit Agreement, $489.9 Agreement”), $492.7 million under our 2028 Convertible Notes, $116.1 million under our 2025 Convertible Notes (together (the “Notes”), with the 2028 Convertible Notes, the “Notes”), and had an additional $750.0 million of aggregate available borrowing capacity up to $750.0 million, with a maximum alternative currency sublimit of $675.0 million, under the revolving credit facility (the “Revolving Credit Facility”) pursuant to the Second Amended Credit Agreement, with the ability to request further increases to the revolving credit facility up to the greater of consolidated EBITDA or $525.0 million.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
It In light of these events, there continues to exist significant uncertainty about the future trade relationships between the U.S. and other countries with respect to such trade policies, treaties, and tariffs and it is difficult to predict what further trade-related actions governments may take, which may include trade restrictions and additional or increased tariffs and export controls imposed on short notice, and we may be unable to quickly and effectively react to or mitigate such actions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Food Failure to comply with those regulations could adversely affect our reputation, ability to do business and Drug Administration (the “FDA”), financial statements.Most of our products are medical devices subject to regulation by the FDA, by other federal and state governmental agencies, by comparable agencies of other countries and regions, by certain accrediting bodies and by regulations governing hazardous materials (or the manufacture and sale of products containing any such materials).
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
As Following the recording of December 31, 2024, $1.1 billion and $0.3 million in goodwill and indefinite-lived intangible assets impairment charges in 2024 and 2023, respectively, the net carrying value of our goodwill and other intangible assets totaled approximately $2.9 billion. $3.0 billion as of December 31, 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, The U.S. has significantly increased tariffs on products imported from China into the U.S. has recently and implemented new tariffs on China and proposed to significantly increase tariffs on foreign imports into the U.S. from other countries, particularly from Canada Canada, Mexico, and Mexico. the EU.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, the deployment of AI artificial intelligence systems could expose us to increased cybersecurity threats, such as data breaches and unauthorized access access, including risks from employees using unauthorized artificial intelligence systems in violation of our artificial intelligence governance policy, leading to financial losses, legal liabilities, and reputational damage.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our failure to repurchase the Notes or to pay the cash amounts due upon conversion when required will constitute a default under the indentures indenture governing the 2028 Convertible Notes and the 2025 Convertible Notes between us and Wilmington Trust, National Association, as trustee, dated as of August 10, 2023 and May 21, 2020, respectively. 2023.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot predict whether additional U.S. and foreign customs quotas, duties (including antidumping or countervailing duties), tariffs, taxes or other charges or restrictions, requirements as to where raw materials must be purchased or other restrictions on our imports will be imposed in the future or adversely modified, whether retaliatory tariffs and trade measures will be imposed by other counties on U.S. exports, or what effect such actions would have on our costs of operations.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
The supply chains for our businesses have also been impacted by global conflicts, including the COVID-19 related lockdowns in China Russia-Ukraine war and the Russia-Ukraine conflict. Israel-Hamas war.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
When growth in the global economy or in any of the markets we serve slows for a significant period, there is significant deterioration in the global economy or such markets or when improvements in the global economy do not benefit the markets we serve, we may be unable to execute on our growth strategy and our business and financial statements could be adversely affected.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Historically, a substantial portion of our sales had come from a limited number of distributors, particularly Henry Schein, which accounted for approximately 12% of our sales in 2025 and 10% of our sales in 2024 and 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
From our IPO through February 7, 2025, 6, 2026, the sales price of our common stock as reported by the NYSE New York Stock Exchange or NYSE, has ranged from a low sales price of $10.08 on March 19, 2020 to a high sales price of $52.03 on March 29, 2022.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Trade policies and disputes at times may result in increased tariffs, trade barriers, and other protectionist measures, which can increase our manufacturing costs, make our products less competitive, reduce demand for our products, limit our ability to sell to certain customers, limit our ability to procure components or raw materials, or impede or slow the movement of our goods across borders.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Increasing protectionism and economic nationalism may lead to further changes in trade policies and regulations, domestic sourcing initiatives, or other formal and informal measures that could make it more difficult to sell our products in, or restrict our access to, some certain markets.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
We also hold certain receivables and payables denominated in a currency other than the U.S. dollar. Movement in the related foreign currency rates in relation to the U.S. dollar may also impact our results of operations.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Geographically, sales volumes were positively impacted by higher sales in North America and Europe.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
For the Years Ended December 31, ($ in millions) 2025 2024 2023 Selling, general and administrative expenses $ 1,156.6 $1,158.0 $1,056.9 Research and development expenses $ 114.0 $99.1 $93.8 Goodwill and intangible asset impairment $ — $1,153.8 $258.3 SG&A as a % of sales 42.5 % 46.1% 41.2% R&D as a % of sales 4.2 % 3.9% 3.7%
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
During the second quarter of 2025, we borrowed from our Revolving Credit Facility to pay in full the $116.3 million in principal amount outstanding on our 2025 Convertible Notes which matured on June 1, 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
In early 2025, we transferred approximately $320 million of international cash to the U.S. Although local laws may restrict the repatriation of certain cash held outside the U.S., most of our foreign cash is available for repatriation. Under current U.S. tax law, cash may generally be repatriated to the U.S. without additional U.S. tax; however, such repatriation may be subject to non-U.S. withholding or other taxes on distributions. Cash held by our non-U.S. subsidiaries that is designated for indefinite reinvestment is primarily used to finance foreign operations and investments, including acquisitions. The income tax effects, if any, applicable to such earnings, including basis differences in our foreign subsidiaries, are not readily determinable or are impracticable to estimate.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
On February 5, 2025, our Board of Directors authorized a stock repurchase program, allowing us to purchase up to $250 million of our outstanding common stock through December 31, 2026. Stock repurchases made in connection with this program totaled approximately $165.9 million, or 9.2 million shares during the year ended December 31, 2025. Refer to Part II, Item 5 “Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities” in this Annual Report on Form 10-K for more details. The cash outflows associated with the Company’s stock repurchases are classified in financing activities in the accompanying Consolidated Statements of Cash Flows.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Additionally, we use foreign currency forward and call option contracts to hedge our foreign currency risk associated with certain foreign denominated balance sheet transactions. These foreign currency forward and call option contracts are not designated as a hedge for accounting purposes and therefore the changes in the fair value of these instruments are recognized immediately in earnings. On December 31, 2025, we entered into various foreign currency forward contracts with an aggregate notional amount of $162.7 million, which had a fair value of zero at December 31, 2025, and matured in January 2026. The realized and unrealized gains (losses) related to forward contracts or call options partially offset the corresponding gains (losses) related to the underlying foreign denominated balance sheet transactions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
For goodwill and indefinite-lived intangible assets we performed our 2025 annual test of impairment on the first day of the fourth quarter. Based on this assessment, our analysis indicated that the fair value of our reporting units and the fair value of our indefinite-lived intangible assets exceeded their carrying values and consequently did not result in an impairment charge for the year ended December 31, 2025. However, any deviation in future actual financial results compared to the forecasted financial results or valuation assumptions used in the impairment tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect on the fair value of either the reporting units or indefinite-lived intangible assets and could result in future impairment charges. There can be no assurance that our future asset impairment testing will not result in a material charge to earnings.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedMD&A
Other (expense) income, net for the year ended December 31, 2024 consists primarily of net losses on investments, offset by net periodic benefit costs. Other expenses, net for the year ended December 31, 2023 consists primarily of $29.0 million of inducement and other expenses associated with the Notes Exchanges, offset by a $3.6 million net gain on investments.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
While repatriation of some cash held outside the United States may be restricted by local laws, most of our foreign cash could be repatriated to the United States. In early 2025, we transferred approximately $320 million in international cash to the United States.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Following enactment of the Tax Cut and Jobs Act of 2017 (“TCJA”) and the associated transition tax, in general, repatriation of cash to the United States can be completed with no incremental U.S. tax; however, repatriation of cash could subject us to non-U.S. jurisdictional taxes on distributions. Additionally, we have determined that unremitted foreign earnings are not considered indefinitely reinvested to the extent foreign earnings can be distributed without a significant tax cost. As such, we have recorded foreign withholding tax liabilities related to the future repatriation of such earnings. We continue to indefinitely reinvest all other outside basis differences to the extent reversal would incur a significant tax liability.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
On August 31, 2023, we entered into the Second Amended Credit Agreement, whereby we entered into the senior term loan facility due 2028 for $530.0 million and the senior euro term loan facility due 2028 for €350.0 million (collectively the “2028 Term Loans”). The Second Amended Credit Agreement also includes a revolving credit facility with an aggregate available borrowing capacity of $750.0 million. The Senior Credit Facilities mature on August 31, 2028, and are subject to an earlier maturity date of 91 days prior to the maturity date of the 2028 Convertible Notes, if more than $250.0 million of such notes are outstanding at that time.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
The proceeds from the Second Amended Credit Agreement were used to repay outstanding indebtedness for the senior term loan facility due 2024 (the “2024 Term Loan”) and the senior euro term loan facility due 2024 (the “2024 Euro Term Loan”). Additionally, we paid fees aggregating approximately $5.2 million in connection with the Second Amended Credit Agreement.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
The Company repaid $100.0 million of the 2028 Term Loan during the year ended December 31, 2024.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
On August 10, 2023, we issued the 2028 Convertible Notes due on August 15, 2028, unless earlier repurchased, redeemed or converted. The aggregate principal amount, which includes the initial purchasers’ exercise in full of their option to purchase an additional $65.2 million principal amount of the 2028 Convertible Notes, was $500.2 million. The net proceeds from the issuance, after deducting purchasers’ discounts and estimated offering expenses, were $485.9 million. We used a portion of the net proceeds to partially exchange the 2025 Convertible Notes. The 2028 Convertible Notes will accrue interest at a rate of 1.75% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2024. The 2028 Convertible Notes have an initial conversion rate of 21.5942 shares of our common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $46.31 per share of our common stock and is subject to adjustment upon the occurrence of specified events. The 2028 Convertible Notes have customary provisions relating to the occurrence of “Events of Default” (as defined in the Indenture governing the 2028 Convertible Notes).
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Concurrently with the offering of the 2028 Convertible Notes, in separate, privately negotiated transactions, we entered into exchange agreements with a limited number of holders of the 2025 Convertible Notes to exchange $401.2 million principal amount of the 2025 Convertible Notes for aggregate consideration of approximately $403.0 million in cash, including accrued interest, and approximately 8.4 million shares of our common stock. We may engage in additional exchanges, or we may repurchase or induce conversions, of the remaining 2025 Convertible Notes.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
In connection with the offering of the 2025 Convertible Notes, we entered into the Capped Calls with certain counterparties. The Capped Calls have an initial strike price of approximately $21.01 per share, subject to certain adjustments, which corresponds to the initial conversion price of the 2025 Convertible Notes. The Capped Calls have initial cap prices of $23.79 per share, subject to certain adjustments. The Capped Calls are generally intended to reduce or offset the potential dilution from shares of common stock issued upon any conversion with such reduction or offset, as the case may be, subject to a cap based on the cap price. The cost of $20.7 million incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Simultaneously with the Notes Exchanges, we also completed a partial unwind of the Capped Calls resulting in a repurchase of 1.0 million shares of our common stock. The Capped Calls will mitigate dilution for the conversion of the remaining 2025 Convertible Notes up to our common stock price of $23.79. If the remaining 2025 Convertible Notes are converted at a price higher than $23.79 per share, the Capped Calls will no longer mitigate dilution from the conversion of the 2025 Convertible Notes.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Our growth strategy contemplates future acquisitions that either strategically fit with our existing portfolio or expand our portfolio. As a result, accounting for such business combinations requires the allocation of purchase price to the various assets and liabilities of the acquired business at their respective fair values. We use all available information to make these fair value determinations. Determining the fair value of assets acquired requires judgement and assumptions regarding future projection of sales and operating margin, including discount rates.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Our goodwill impairment analysis at June 28, 2024 indicated that the fair value of five of our eight reporting units did not exceed their carrying values and consequently resulted in a $960.5 million impairment charge. The excess of the estimated fair value over carrying value (expressed as a percentage of carrying value for the respective reporting unit) for the three reporting units not impaired, ranged from approximately 38% to approximately 88%, and zero for the five reporting units with impairments. In order to evaluate the sensitivity of the fair value calculations used in the goodwill impairment test, we applied a hypothetical 10% decrease to the fair values of each reporting unit and compared those hypothetical values to the reporting unit carrying values. Based on this hypothetical 10% decrease, the excess of the estimated fair value over carrying value (expressed as a percentage of carrying value for the respective reporting unit) for the three reporting units not impaired, ranged from approximately 24% to approximately 69%. For the five impaired reporting units, the application of a hypothetical 10% decrease in fair value would result in an additional impairment of approximately $289 million.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, ($ in millions) 2025 2024 2023 2022 Net cash provided by operating activities $ 275.7 $ 336.5 $ 275.7 $ 182.7 Payments for additions to property, plant and equipment $ (45.3) $ (33.8) $ (58.2) $ (75.7) Purchases of investments held in rabbi trust (9.9) (32.8) — — Proceeds from sale of investments held in rabbi trust 10.4 9.3 — — Proceeds from sales of property, plant and equipment 0.5 0.1 6.1 3.3 Proceeds from sale of equity investment — 0.4 10.7 — Acquisitions, net of cash acquired — — (696.2) Proceeds from sale of KaVo Treatment Unit and Instrument Business — — 73.9 Proceeds from the settlement of derivative financial instruments 2.5 1.6 56.0 All other investing activities (0.3) (22.6) (18.6) (6.8) 2.2 (21.0) Net cash used in investing activities $ (51.1) $ (54.6) $ (62.4) $ (657.3) Proceeds from stock option exercises $ 2.8 $ 2.4 $ 11.3 $ 21.8 Cash paid for treasury stock (166.6) — — Tax withholding payment related to net settlement of equity awards (6.2) (5.3) (7.9) (9.1) Proceeds from issuance of convertible notes due 2028 — — 500.2 — Debt issuance costs related to issuance of convertible notes due 2028 — — (13.8) — Principal paid related to exchange of convertible notes due 2025 (116.3) — (401.2) — Proceeds from borrowing — — 323.5 0.3 Repayments of borrowing — (100.0) (288.8) (0.5) Proceeds from revolving line of credit 115.4 — — Debt issuance costs related to other borrowings — — (4.5) — Proceeds from revolving line of credit — — 124.0 Repayment of revolving line of credit — — (124.0) All other financing activities — (0.8) 0.1 — Net cash (used in) provided by financing activities $ (170.9) $ (103.7) $ 118.9 $ 12.5
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in operating profit margin was primarily due to lower sales, higher sales volume, including the impact from changes to the timing of deferred revenue deferral recognition related to our clear aligner treatment plans, higher sales price, lower bad debt expense, manufacturing productivity, and the absence of impairment of certain long-lived assets, assets from the comparable prior period, partially offset by increased tariffs, higher costs due to the impact of unfavorable product mix, lower period-over-period savings associated with productivity improvements, higher bad debt costs, foreign exchange rates and our continuing investment in our long-term growth initiatives.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in financing activities was $103.7 $170.9 million during the year ended December 31, 2024, 2025, compared to net cash provided by used in financing activities of $118.9 $103.7 million for the comparable period of 2023 2024 and was primarily due to a driven by stock repurchases and the repayment of the 2025 Convertible Notes which matured on June 1, 2025, partially offset by the borrowings under the Revolving Credit Facility and the repayment of $100.0 million of the 2028 Term Loan during 2024 compared to net borrowings during 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cost of sales and decrease in gross profit margin during the year ended December 31, 2024, 2025, as compared to the comparable period in 2023, 2024, was driven primarily driven by higher sales volume, higher costs due to the unfavorable product mix, impact of foreign currency exchange rates, and increased tariffs, partially offset by the absence of impairment of related to certain long-lived assets and lower period-over-period savings associated with productivity improvements. from the comparable prior period.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in SG&A expenses as a percentage of sales for the year ended December 31, 2024, 2025, as compared to the comparable period of 2023, 2024, was driven primarily due to by higher sales and marketing investments, increased compensation, increased sales, along with lower bad debt, higher restructuring amortization of intangible assets, legal settlement costs, and higher legal settlement general and administrative costs, partially offset by a decrease our continuing investment in amortization of intangible assets. our long-term growth initiatives.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Operating profit margin was 17.0% 16.3% for the year ended December 31, 2024, 2025, as compared to an operating profit margin of 16.9% 17.0% for the comparable period of 2023. 2024, primarily due to the impact of unfavorable foreign exchange rates, unfavorable product mix, increased tariffs, partially offset by higher sales volume and sales price and a decrease in amortization of intangibles.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Any future weakening of the U.S. dollar against major currencies would positively impact our sales and results of operations and any strengthening of the U.S. dollar against major currencies would adversely impact our sales and results of operations and any weakening of the U.S. dollar against major currencies would positively impact our sales and results of operations.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in sales and core sales increase was primarily due to changes to an increase in sales volume coupled with the timing of deferred revenue deferral recognition related to our clear aligner treatment plans plans, which positively impacted sales by 4.5% on a period-over-period basis. basis, while sales price increased by 2.0%.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We also For the year ended December 31, 2024, we recorded goodwill impairment charges as a result of our annual goodwill impairment test during the year ended 2023, analysis at June 28, 2024, whereby we recorded a pre-tax goodwill impairment charge of $212.3 $960.5 million, with $134.5 $707.8 million related to our Specialty Products & Technologies segment and $77.8 $252.7 million related to our Equipment & Consumables segment, and a $46.0 $101.1 million indefinite-lived intangible asset impairment related to certain indefinite-lived trade names within our the Specialty Products & Technologies segment.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Sales and core sales growth for the year ended December 31, 2024 decreased 1.6% 2025 increased 8.1% and 0.9%, 6.9%, respectively, compared to the comparable period in 2023. 2024, driven primarily by an increase in sales price of 3.8%, coupled with an increase in sales volume of 3.1% on a period-over-period basis.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, The U.S. has significantly increased tariffs on products imported from China into the U.S. has recently and implemented new tariffs on China and proposed to significantly increase tariffs on foreign imports into the U.S. from other countries, particularly from Canada Canada, Mexico, and Mexico. the EU.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The change in the effective rate was primarily due to larger the impact of nondeductible impairment charges for goodwill and intangible assets in 2024 and a change in the current year compared indefinite reinvestment assertion related to the prior year. restructuring of a foreign subsidiary with certain intercompany loans in 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesMD&A
Increasing protectionism and economic nationalism may lead to further changes in trade policies and regulations, domestic sourcing initiatives, or other formal and informal measures that could make it more difficult to sell our products in, or restrict our access to, some to certain markets.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new